Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Expanding Opioid REMS To Immediate Release Formulations

Executive Summary

Commissioner Gottlieb tells opioid scientific workshop that updated REMS will also require training to be available to nurses and pharmacists; agency beginning new study on prescriber perceptions.


Related Content

Initiator Or Facilitator? Gottlieb Reflects On First Year As Head Of US FDA
Opioids: US Senate Committee Chairman's Discussion Drafts Broadly Reflect FDA Priorities
Opioid Industry's 'Superstructure' Targeted By State Attorneys General
Opioid Cough Medicines Might Face Complete Ban In Pediatric Patients
Curtain Falls On Opana ER As Endo Agrees To US FDA Withdrawal Request
Opioid Prescriber Training: US FDA Still Debating Mandate; CMS Policies Having Impact Now
Opioid REMS: New CME 'Blueprint' To Include Immediate-Release Drugs
Opioid Policy At US FDA To Become 'More Forceful,' Gottlieb Says
REMS Assessment Challenges Shine Through In Opioids Review
Restrictive REMS Is Least Favored Path For Opioid Prescriber Education


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts